The Use of Blood Products in Patients Undergoing Cardiac Surgery
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Anemia
- Sponsor
- University of Turku
- Enrollment
- 31000
- Primary Endpoint
- Red blood cell infusions
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
Blood transfusion is a common procedure essential for the treatment of patients undergoing cardiac surgery. Inappropriate transfusions, however, not only incur needless healthcare costs, but increase unnecessary risks due to transfusion reactions and infectious and immunomodulative causes. Safe and appropriate patient care requires evaluated blood component prescription practices.
Practically all patients undergoing cardiac surgery in Finland have a blood product booking from the Finnish Red Cross Blood Service. This registry contains large volumes of transfusion-related information on all Finnish patients undergoing cardiac surgery in Finnish centers. Participating hospitals were scattered to all geographical areas in Finland and concentrated to the most populated regions.
Data on the blood product use, laboratory findings one month pre-operatively and 12 months post-operatively were available.
Finnish hospitals have been required to provide information on hospital visits for the Finnish National Research and Development Centre for Welfare and Health for healthcare planning purposes. We used in part the original data sent by hospitals to the Finnish Hospital Discharge Register (FHDR).
Detailed Description
Registry includes * \>21 000 patients who underwent coronary bypass, * \>4500 patients with aortic valve replacement, * \>4000 mitral valve operation.
Investigators
Dr. Pirjo Mustonen, MD, PhD
Professor
University of Turku
Eligibility Criteria
Inclusion Criteria
- •Cardiac surgery performed in Finnish University and Central hospitals
- •Blood product booking for surgery
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Red blood cell infusions
Time Frame: 12 months
Platelet infusion
Time Frame: 12 months
Fresh frozen plasma
Time Frame: 12 months
Octaplas
Time Frame: 12 months
Secondary Outcomes
- TIA/stroke/arterial embolism(12)
- re-operation due to bleeding(12 months)
- myocardial infarction(12 months)
- All cause mortality(12 months)